Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 3/20 | 0.35 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174275 | 1.00 | GAA (0.41) | GAARAB9AKMT2APOLBMEN1 | |
| SCHEMBL2174285 | 1.00 | GAA (0.41) | GAARAB9AKMT2APOLBMEN1 | |
| SCHEMBL3005542 | 0.84 | GFER (0.40) | RAB9AKMT2AMEN1LMNACTSG | |
| SCHEMBL13794593 | 0.84 | ESR2 (0.45) | GAAKMT2APOLBMEN1LMNA | |
| SCHEMBL3004818 | 0.84 | TDP1 (0.39) | GAAKMT2AMEN1LMNAPTGS2 | |
| SCHEMBL3002914 | 0.84 | NPSR1 (0.36) | KMT2APOLB | |
| SCHEMBL2996862 | 0.83 | MGLL (0.38) | KMT2APOLBMEN1ALOX5 | |
| SCHEMBL3001897 | 0.83 | ALDH1A1 (0.39) | GAAKMT2APOLBMEN1LMNA | |
| SCHEMBL3014011 | 0.83 | POLB (0.49) | KMT2APOLBMEN1 | |
| SCHEMBL3003865 | 0.83 | L3MBTL1 (0.44) | KMT2APOLBMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973066-B2 | Pyrrolo[1,2-A]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | NEUROTUNE AG (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973066-B2 | Pyrrolo[1,2-A]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | NEUROTUNE AG (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973066-B2 | Pyrrolo[1,2-A]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | NEUROTUNE AG (CH) | 2011-07-05 | — | — | US | disclosed |
| EP-2094265-B1 | PYRROLOY[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | NEUROTUNE AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| EP-2094265-B1 | PYRROLOY[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | NEUROTUNE AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20100062077-A1 | PYRROLO[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | NEUROTUNE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100062077-A1 | PYRROLO[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | NEUROTUNE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100062077-A1 | PYRROLO[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | NEUROTUNE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-2094265-A1 | PYRROLOY[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | Neurotune AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| EP-1925304-A1 | Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | NIKEM RESEARCH S.R.L. (IT) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008058988-A1 | PYRROLO[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | NEUROTUNE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008058988-A1 | PYRROLO[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | NEUROTUNE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062077-A1 | PYRROLO[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS | CIP2A, IPO5, AIFM1 | GAA 3613/4885RAB9A 1917/4885KMT2A 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.